Ghatak Dishari, Das Ghosh Damayanti, Roychoudhury Susanta
Cancer Biology and Inflammatory Disorder Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Division of Research, Saroj Gupta Cancer Centre and Research Institute, Kolkata, India.
Front Oncol. 2021 Jan 11;10:604124. doi: 10.3389/fonc.2020.604124. eCollection 2020.
The tumor suppressor p53 maintains an equilibrium between self-renewal and differentiation to sustain a limited repertoire of stem cells for proper development and maintenance of tissue homeostasis. Inactivation of p53 disrupts this balance and promotes pluripotency and somatic cell reprogramming. A few reports in recent years have indicated that prevalent oncogenic (GOF) mutations further boosts the stemness properties of cancer cells. In this review, we discuss the role of wild type p53 in regulating pluripotency of normal stem cells and various mechanisms that control the balance between self-renewal and differentiation in embryonic and adult stem cells. We also highlight how inactivating and GOF mutations in p53 stimulate stemness in cancer cells. Further, we have explored the various mechanisms of mutant p53-driven cancer stemness, particularly emphasizing on the non-coding RNA mediated epigenetic regulation. We have also analyzed the association of cancer stemness with other crucial properties of mutant p53 such as epithelial to mesenchymal transition phenotypes and chemoresistance to understand how activation of one affects the other. Given the critical role of cancer stem-like cells in tumor maintenance, cancer progression, and therapy resistance of mutant p53 tumors, targeting them might improve therapeutic efficacy in human cancers with mutations.
肿瘤抑制因子p53维持自我更新与分化之间的平衡,以维持有限的干细胞库,促进组织正常发育和维持组织稳态。p53失活会破坏这种平衡,促进多能性和体细胞重编程。近年来的一些报道表明,普遍存在的致癌(功能获得性)突变会进一步增强癌细胞的干性。在这篇综述中,我们讨论了野生型p53在调节正常干细胞多能性中的作用,以及控制胚胎干细胞和成体干细胞自我更新与分化平衡的各种机制。我们还强调了p53的失活和功能获得性突变如何刺激癌细胞的干性。此外,我们探讨了突变型p53驱动癌症干性的各种机制,特别强调了非编码RNA介导的表观遗传调控。我们还分析了癌症干性与突变型p53的其他关键特性(如上皮-间质转化表型和化疗耐药性)之间的关联,以了解一种特性的激活如何影响另一种特性。鉴于癌症干细胞样细胞在突变型p53肿瘤的肿瘤维持、癌症进展和治疗耐药性中的关键作用,靶向这些细胞可能会提高对人类癌症突变患者的治疗效果。